» Articles » PMID: 25575823

DNA Damage Induces GDNF Secretion in the Tumor Microenvironment with Paracrine Effects Promoting Prostate Cancer Treatment Resistance

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Jan 11
PMID 25575823
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Though metastatic cancers often initially respond to genotoxic therapeutics, acquired resistance is common. In addition to cytotoxic effects on tumor cells, DNA damaging agents such as ionizing radiation and chemotherapy induce injury in benign cells of the tumor microenvironment resulting in the production of paracrine-acting factors capable of promoting tumor resistance phenotypes. In studies designed to characterize the responses of prostate and bone stromal cells to genotoxic stress, we found that transcripts encoding glial cell line-derived neurotrophic factor (GDNF) increased several fold following exposures to cytotoxic agents including radiation, the topoisomerase inhibitor mitoxantrone and the microtubule poison docetaxel. Fibroblast GDNF exerted paracrine effects toward prostate cancer cells resulting in enhanced tumor cell proliferation and invasion, and these effects were concordant with the expression of known GDNF receptors GFRA1 and RET. Exposure to GDNF also induced tumor cell resistance to mitoxantrone and docetaxel chemotherapy. Together, these findings support an important role for tumor microenvironment damage responses in modulating treatment resistance and identify the GDNF signaling pathway as a potential target for improving responses to conventional genotoxic therapeutics.

Citing Articles

Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity.

Shi P, Lin Z, Song Y, Li Z, Zeng M, Luo L J Cancer Res Clin Oncol. 2024; 150(3):159.

PMID: 38530432 PMC: 10965586. DOI: 10.1007/s00432-024-05692-8.


The contribution of the nervous system in the cancer progression.

Park H, Lee C BMB Rep. 2024; 57(4):167-175.

PMID: 38523371 PMC: 11058356.


Nanomedicine Strategies for Targeting Tumor Stroma.

Su M, Nethi S, Dhanyamraju P, Prabha S Cancers (Basel). 2023; 15(16).

PMID: 37627173 PMC: 10452920. DOI: 10.3390/cancers15164145.


Unveiling the Neural Environment in Cancer: Exploring the Role of Neural Circuit Players and Potential Therapeutic Strategies.

Nguyen T, Ngoc D, Choi J, Lee C Cells. 2023; 12(15).

PMID: 37566075 PMC: 10417274. DOI: 10.3390/cells12151996.


A network map of GDNF/RET signaling pathway in physiological and pathological conditions.

Mol P, Devasahayam Arokia Balaya R, Dagamajalu S, Babu S, Chandrasekaran P, Raghavan R J Cell Commun Signal. 2023; 17(3):1089-1095.

PMID: 36715855 PMC: 10409931. DOI: 10.1007/s12079-023-00726-1.


References
1.
Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N . Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31(5):578-83. DOI: 10.1053/hp.2000.6698. View

2.
Mottet N, Clarke N, De Santis M, Zattoni F, Morote J, Joniau S . Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. BJU Int. 2014; 115(3):364-72. DOI: 10.1111/bju.12736. View

3.
Gmyrek G, Walburg M, Webb C, Yu H, You X, Vaughan E . Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol. 2001; 159(2):579-90. PMC: 1850543. DOI: 10.1016/S0002-9440(10)61729-4. View

4.
Airaksinen M, Saarma M . The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002; 3(5):383-94. DOI: 10.1038/nrn812. View

5.
Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan M . Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res. 2003; 159(4):439-52. DOI: 10.1667/0033-7587(2003)159[0439:egfair]2.0.co;2. View